Workflow
Tevogen Bio(TVGN)
icon
Search documents
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
GlobeNewswire News Room· 2024-07-08 20:07
"I share Marc's belief that business success must coexist with social prosperity," said Dr. Ryan Saadi. "As a Yale graduate and a member of the Yale School of Public Health Leadership Council, it was a distinct pleasure to join Yale School of Management Senior Associate Dean, Jeffrey Sonnenfeld and business pioneers including Nikesh Arora, CEO, Palo Alto Networks; Steven Bandrowczak, CEO, Xerox; Ivan Seidenberg, Former Chair & CEO, Verizon; Brian Moynihan, Chair & CEO, Bank of America; Ken Moelis, Founder, ...
Tevogen Bio(TVGN) - 2024 Q1 - Quarterly Report
2024-05-28 21:22
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-41002 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) (State or other jur ...
Tevogen Bio(TVGN) - 2023 Q4 - Annual Report
2024-04-27 01:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 For the transition period from ______ to ______ Commission file number: 001-41002 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 85-1284695 (State or o ...
Tevogen Bio(TVGN) - 2024 Q1 - Quarterly Results
2024-04-26 12:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 Tevogen Bio Holdings Inc. (Exact name of registrant as specified in its charter) Delaware 001-41002 85-1284695 (State or other jurisdiction of incorporation) 15 Independence Boulevard, Suite #410 Warren, New Jersey 07059 (Address of principal executive offices) (Zip Code) Registr ...
Tevogen Bio(TVGN) - 2023 Q3 - Quarterly Report
2023-11-13 22:14
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41002 (913) 579-4170 (Registrant's telephone number, including area code) Not applicable (Former name, former address and former f ...
Tevogen Bio(TVGN) - 2023 Q2 - Quarterly Report
2023-08-21 20:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41002 SEMPER PARATUS ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other ...
Tevogen Bio(TVGN) - 2023 Q1 - Quarterly Report
2023-05-22 21:08
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the quarterly period ended March 31, 2023 (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41002 SEMPER PARATUS ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) Cayman Islands N ...
Tevogen Bio(TVGN) - 2022 Q4 - Annual Report
2023-04-17 21:12
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41002 Semper Paratus Acquisition Corporation (Exact name of registrant as specified in its charter) | Cayman Islands ...
Tevogen Bio(TVGN) - 2022 Q2 - Quarterly Report
2022-08-15 20:37
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41002 SEMPER PARATUS ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) Cayman Islands N/ ...
Tevogen Bio(TVGN) - 2022 Q1 - Quarterly Report
2022-05-17 01:01
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents Commission File No. 001-41002 SEMPER PARATUS ACQUISITION CORPORATION (Exact name of registrant as specified in its charter) (913) 579-4170 C ...